Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial.

Introduction: Amivantamab plus lazertinib significantly improved progression-free and overall survival versus osimertinib in patients with previously untreated, EGFR-mutant advanced NSCLC. EGFR-targeted therapies are associated with dermatologic adverse events (AEs), which can affect quality of life (QoL). COCOON was conducted to assess prophylactic management and improve treatment experience.

Overall Survival with Amivantamab-Lazertinib in -Mutated Advanced NSCLC.

Background: Previous results from this phase 3 trial showed that progression-free survival among participants with previously untreated (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC) was significantly improved with amivantamab-lazertinib as compared with osimertinib. Results of the protocol-specified final overall survival analysis in this trial have not been reported.

Methods: We randomly assigned, in a 2:2:1 ratio, participants with previously untreated -mutated (exon 19 deletion or L858R substitution), locally advanced or metastatic NSCLC to receive amivantamab-lazertinib, osimertinib, or lazertinib.

Thunberg root extract inhibits atopic dermatitis-like skin symptoms.

Thunberg is a perennial herbaceous plant of the genus that belongs to the Apiaceae family and is effective in improving inflammation, gout, and dizziness. However, the skin pruritus improvement effect and mechanism of action of Thunberg root extract (PJRE) have not yet been reported. We investigated the effects of PJRE on the regulation of pruritus and inflammatory responses in compound 48/80 (C48/80)-treated mice, phorbol 12-myristate 13-acetate (PMA)/A23187-induced human skin mast cells, and LPS-stimulated mouse macrophages.

Asian Subgroup Analysis of Patients in the Phase 2 DeLLphi-301 Study of Tarlatamab for Previously Treated Small Cell Lung Cancer.

Introduction: Tarlatamab is a bispecific T-cell engager (BiTE) immunotherapy that binds delta-like ligand 3 on the surface of small cell lung cancer (SCLC) cells and CD3 on T cells, facilitating T cell-mediated cancer cell lysis. In the primary analysis of the phase 2 DeLLphi-301 study (NCT05060016), tarlatamab showed a favourable benefit-to-risk profile with durable objective responses and promising survival outcomes in patients with previously treated SCLC. Here, phase 2 data for the Asia region subgroup are presented.

-propolis mixture attenuates airway inflammation in a mouse model of PM and ovalbumin-induced respiratory disease.

Airway inflammation driven by particulate matter (PM) exposure underlies diseases such as asthma and allergic rhinitis. Although conventional anti-inflammatory therapies exist, they often cause significant side effects. Natural plant extracts offer non-toxic alternatives with comparable efficacy.